JP2018526333A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526333A5 JP2018526333A5 JP2017568076A JP2017568076A JP2018526333A5 JP 2018526333 A5 JP2018526333 A5 JP 2018526333A5 JP 2017568076 A JP2017568076 A JP 2017568076A JP 2017568076 A JP2017568076 A JP 2017568076A JP 2018526333 A5 JP2018526333 A5 JP 2018526333A5
- Authority
- JP
- Japan
- Prior art keywords
- cysteine
- peptide
- pharmaceutical composition
- lysine
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021034966A JP7626393B2 (ja) | 2015-06-30 | 2021-03-05 | グルカゴン誘導体及びその持続型結合体を含む組成物 |
| JP2023019975A JP2023062043A (ja) | 2015-06-30 | 2023-02-13 | グルカゴン誘導体及びその持続型結合体を含む組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2015-0093265 | 2015-06-30 | ||
| KR20150093265 | 2015-06-30 | ||
| PCT/KR2016/006984 WO2017003191A1 (en) | 2015-06-30 | 2016-06-29 | Glucagon derivative and a composition comprising a long acting conjugate of the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021034966A Division JP7626393B2 (ja) | 2015-06-30 | 2021-03-05 | グルカゴン誘導体及びその持続型結合体を含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526333A JP2018526333A (ja) | 2018-09-13 |
| JP2018526333A5 true JP2018526333A5 (OSRAM) | 2019-07-11 |
| JP6882210B2 JP6882210B2 (ja) | 2021-06-02 |
Family
ID=57608802
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568076A Active JP6882210B2 (ja) | 2015-06-30 | 2016-06-29 | グルカゴン誘導体及びその持続型結合体を含む組成物 |
| JP2021034966A Active JP7626393B2 (ja) | 2015-06-30 | 2021-03-05 | グルカゴン誘導体及びその持続型結合体を含む組成物 |
| JP2023019975A Pending JP2023062043A (ja) | 2015-06-30 | 2023-02-13 | グルカゴン誘導体及びその持続型結合体を含む組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021034966A Active JP7626393B2 (ja) | 2015-06-30 | 2021-03-05 | グルカゴン誘導体及びその持続型結合体を含む組成物 |
| JP2023019975A Pending JP2023062043A (ja) | 2015-06-30 | 2023-02-13 | グルカゴン誘導体及びその持続型結合体を含む組成物 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10696725B2 (OSRAM) |
| EP (3) | EP3322437B1 (OSRAM) |
| JP (3) | JP6882210B2 (OSRAM) |
| KR (2) | KR102005456B1 (OSRAM) |
| CN (1) | CN108025041A (OSRAM) |
| AR (1) | AR105485A1 (OSRAM) |
| AU (2) | AU2016287209B2 (OSRAM) |
| CA (2) | CA2991107C (OSRAM) |
| CL (5) | CL2017003402A1 (OSRAM) |
| CO (1) | CO2018000303A2 (OSRAM) |
| CR (1) | CR20180034A (OSRAM) |
| DK (1) | DK3322437T5 (OSRAM) |
| DO (1) | DOP2017000318A (OSRAM) |
| EA (1) | EA201890058A1 (OSRAM) |
| EC (1) | ECSP18003879A (OSRAM) |
| ES (1) | ES2973017T3 (OSRAM) |
| FI (1) | FI3322437T3 (OSRAM) |
| HU (1) | HUE066226T2 (OSRAM) |
| IL (2) | IL256619B (OSRAM) |
| MA (2) | MA41887B1 (OSRAM) |
| MX (1) | MX2017016845A (OSRAM) |
| PE (2) | PE20180449A1 (OSRAM) |
| PH (1) | PH12017502393A1 (OSRAM) |
| PL (1) | PL3322437T3 (OSRAM) |
| PT (1) | PT3322437T (OSRAM) |
| PY (1) | PY1640586A (OSRAM) |
| TN (1) | TN2017000555A1 (OSRAM) |
| TW (1) | TWI713541B (OSRAM) |
| UA (1) | UA127445C2 (OSRAM) |
| UY (1) | UY36759A (OSRAM) |
| WO (1) | WO2017003191A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| CR20170293A (es) * | 2014-12-30 | 2017-11-03 | Hanmi Pharm Ind Co Ltd | Derivados de glucagón con estabilidad mejorada |
| TN2017000555A1 (en) * | 2015-06-30 | 2019-04-12 | Hanmi Pharm Ind Co Ltd | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| SG11201811697SA (en) * | 2016-06-29 | 2019-01-30 | Hanmi Pharmaceutical Co Ltd | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
| AU2018215840A1 (en) * | 2017-02-03 | 2019-08-01 | Hanmi Pharm. Co., Ltd. | Long-Acting Conjugate Of A Physiologically Active Material And Use Thereof |
| KR20180091773A (ko) | 2017-02-07 | 2018-08-16 | 한미약품 주식회사 | 비펩티드성 중합체 링커 화합물, 그 링커 화합물을 포함하는 결합체, 및 이들의 제조방법 |
| JP2020535199A (ja) * | 2017-09-29 | 2020-12-03 | ハンミ ファーマシューティカル カンパニー リミテッド | 効力が向上した持続性タンパク質結合体 |
| KR20200135618A (ko) * | 2019-05-23 | 2020-12-03 | ㈜ 디앤디파마텍 | 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물 |
| WO2020017919A1 (ko) * | 2018-07-19 | 2020-01-23 | 한미정밀화학주식회사 | 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법 |
| JP2021530533A (ja) * | 2018-07-19 | 2021-11-11 | ディーアンドディー ファーマテック インコーポレイテッド | ポリペプチドを含む医薬組成物 |
| KR101990075B1 (ko) * | 2018-07-19 | 2019-06-18 | ㈜ 디앤디파마텍 | 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물 |
| US20210338779A1 (en) * | 2018-10-04 | 2021-11-04 | Hanmi Pharm. Co., Ltd | Therapeutic use of glucagon and combination including the same |
| CN109239346B (zh) * | 2018-10-31 | 2019-10-11 | 中国药科大学 | 一组代谢标志物在代谢综合征早期诊断方面的应用 |
| AU2019405389B2 (en) * | 2018-12-21 | 2025-06-05 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition containing insulin and glucagon |
| US20220288169A1 (en) * | 2019-05-24 | 2022-09-15 | The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College | Compositions and methods for the treatment and prevention of hypoglycemic complications |
| SG11202105435PA (en) * | 2019-06-28 | 2021-06-29 | Hanmi Pharmaceutical Co Ltd | Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease |
| WO2021066600A1 (ko) * | 2019-10-04 | 2021-04-08 | 한미약품 주식회사 | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 |
| CN112898406B (zh) * | 2019-10-12 | 2023-11-10 | 深圳纳福生物医药有限公司 | 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用 |
| JP7752619B2 (ja) * | 2020-02-21 | 2025-10-10 | スピットファイア ファーマ エルエルシー | Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法 |
| IL298396A (en) * | 2020-05-22 | 2023-01-01 | Hanmi Pharm Ind Co Ltd | Liquid formulation of long-acting conjugate of glucagon derivative |
| CN116096397A (zh) | 2020-07-15 | 2023-05-09 | 韩美药品株式会社 | 胰高血糖素衍生物或其缀合物对于肝脏疾病的治疗用途 |
| JP2023538236A (ja) * | 2020-08-14 | 2023-09-07 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物 |
| WO2022080986A1 (ko) * | 2020-10-16 | 2022-04-21 | 한미약품 주식회사 | Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물 |
| US12171806B2 (en) | 2021-09-28 | 2024-12-24 | Spitfire Pharma Llc | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists |
| AU2022254588A1 (en) | 2021-04-09 | 2023-09-21 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for preventing or treating chronic renal disease including glucagon derivative |
| KR20230095666A (ko) | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 간 표적 물질 및 이의 용도 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
| GB9423277D0 (en) | 1994-11-18 | 1995-01-11 | Univ Nottingham | Pulsed laser deposition of coatings |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| JP2005501058A (ja) | 2001-07-31 | 2005-01-13 | ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ | Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用 |
| AU2004231461B2 (en) | 2003-03-19 | 2009-11-12 | Eli Lilly And Company | Polyethelene glycol linked GLP-1 compounds |
| WO2005047337A1 (en) * | 2003-11-13 | 2005-05-26 | Hanmi Pharmaceutical Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
| US8263084B2 (en) * | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| EP2471810A1 (en) * | 2006-02-22 | 2012-07-04 | Merck Sharp & Dohme Corporation | Oxyntomodulin derivatives |
| AU2007240313B2 (en) | 2006-04-20 | 2012-02-02 | Amgen Inc. | GLP-1 compounds |
| US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| CN101578102B (zh) | 2007-01-05 | 2013-07-17 | 印第安纳大学研究及科技有限公司 | 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物 |
| MX2009008241A (es) | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
| JP5385266B2 (ja) | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| KR20100049032A (ko) | 2007-06-19 | 2010-05-11 | 오츠카 가가쿠 가부시키가이샤 | 당사슬 부가 ｇｌｐ―１ 펩티드 |
| ES2672770T3 (es) | 2007-09-05 | 2018-06-18 | Novo Nordisk A/S | Derivados del péptido-1 similar al glucagón y su uso farmacéutico |
| WO2009099763A1 (en) | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| EP2300037B1 (en) | 2008-06-17 | 2016-03-30 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| TWI474835B (zh) | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑 |
| TWI541023B (zh) * | 2008-06-17 | 2016-07-11 | 印第安納大學科技研究公司 | 在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物 |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| AP3329A (en) | 2009-07-13 | 2015-06-30 | Zealand Pharma As | Acylated glucagon analogues |
| GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| US8703701B2 (en) * | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| EA026384B1 (ru) | 2010-01-20 | 2017-04-28 | Зилэнд Фарма А/С | Лечение заболеваний сердца |
| EP2552950A1 (en) | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
| WO2011143208A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
| KR101382593B1 (ko) * | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| WO2012088116A2 (en) | 2010-12-22 | 2012-06-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| KR102011924B1 (ko) | 2011-05-18 | 2019-08-21 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 제약 |
| UA126465C2 (uk) | 2011-06-10 | 2022-10-12 | Ханмі Сайенс Ко., Лтд. | Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить |
| PL2721062T3 (pl) | 2011-06-17 | 2019-05-31 | Hanmi Science Co Ltd | Koniugat zawierający oksyntomodulinę oraz fragment immunoglobuliny i jego zastosowanie |
| EP2729493B1 (en) | 2011-07-04 | 2020-06-10 | IP2IPO Innovations Limited | Novel compounds and their effects on feeding behaviour |
| HK1198810A1 (en) | 2011-11-17 | 2015-06-12 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| WO2013120022A2 (en) | 2012-02-08 | 2013-08-15 | Seneb Biosciences, Inc. | Treatment of hypoglycemia |
| KR101665009B1 (ko) * | 2012-03-09 | 2016-10-11 | 한미사이언스 주식회사 | 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물 |
| WO2013170636A1 (zh) | 2012-05-18 | 2013-11-21 | 爱德迪安（北京）生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
| CN104583233B (zh) | 2012-06-21 | 2018-10-23 | 印第安纳大学研究及科技有限公司 | 表现出gip受体活性的胰高血糖素的类似物 |
| US9340600B2 (en) | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| PT2916819T (pt) | 2012-11-06 | 2019-10-28 | Hanmi Pharm Ind Co Ltd | Formulação líquida de conjugado proteico que compreende a oxintomodulina e um fragmento de imunoglobulina. |
| EP3444281B1 (en) | 2012-11-20 | 2021-11-03 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| JP6525456B2 (ja) | 2012-11-20 | 2019-06-05 | メデリス ダイアビーティーズ，エルエルシー | インスリン抵抗性のための改善されたペプチド製剤 |
| JP2016506401A (ja) | 2012-12-21 | 2016-03-03 | サノフイ | 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体 |
| MY174727A (en) | 2013-04-18 | 2020-05-11 | Novo Nordisk As | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| WO2015022420A1 (en) | 2013-08-16 | 2015-02-19 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| KR102455171B1 (ko) | 2013-12-18 | 2022-10-14 | 더 스크립스 리서치 인스티튜트 | 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물 |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| AR100695A1 (es) | 2014-05-30 | 2016-10-26 | Hanmi Pharm Ind Co Ltd | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| WO2016077806A1 (en) * | 2014-11-13 | 2016-05-19 | AskGene Pharma, Inc. | Fusion proteins with dual receptor agonist activities |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| CR20170293A (es) * | 2014-12-30 | 2017-11-03 | Hanmi Pharm Ind Co Ltd | Derivados de glucagón con estabilidad mejorada |
| TN2017000555A1 (en) | 2015-06-30 | 2019-04-12 | Hanmi Pharm Ind Co Ltd | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| US20170004368A1 (en) | 2015-07-05 | 2017-01-05 | Neteera Technologies Ltd. | System and method for biometric detection based on sweat ducts |
| TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物 |
| JP6989503B2 (ja) | 2015-12-02 | 2022-01-05 | ハンミ ファーマシューティカル カンパニー リミテッド | 脂肪酸誘導体を用いたタンパク質結合体及びその製造方法 |
| JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
-
2016
- 2016-06-29 TN TNP/2017/000555A patent/TN2017000555A1/en unknown
- 2016-06-29 EP EP16818224.4A patent/EP3322437B1/en active Active
- 2016-06-29 PE PE2017002855A patent/PE20180449A1/es unknown
- 2016-06-29 WO PCT/KR2016/006984 patent/WO2017003191A1/en not_active Ceased
- 2016-06-29 JP JP2017568076A patent/JP6882210B2/ja active Active
- 2016-06-29 HU HUE16818224A patent/HUE066226T2/hu unknown
- 2016-06-29 EP EP25153425.1A patent/EP4523705A3/en active Pending
- 2016-06-29 CN CN201680048764.5A patent/CN108025041A/zh active Pending
- 2016-06-29 EA EA201890058A patent/EA201890058A1/ru unknown
- 2016-06-29 DK DK16818224.4T patent/DK3322437T5/da active
- 2016-06-29 PL PL16818224.4T patent/PL3322437T3/pl unknown
- 2016-06-29 UA UAA201800030A patent/UA127445C2/uk unknown
- 2016-06-29 CA CA2991107A patent/CA2991107C/en active Active
- 2016-06-29 MX MX2017016845A patent/MX2017016845A/es unknown
- 2016-06-29 MA MA41887A patent/MA41887B1/fr unknown
- 2016-06-29 MA MA49545A patent/MA49545B1/fr unknown
- 2016-06-29 EP EP23214927.8A patent/EP4324519A3/en not_active Withdrawn
- 2016-06-29 ES ES16818224T patent/ES2973017T3/es active Active
- 2016-06-29 PE PE2023001338A patent/PE20240215A1/es unknown
- 2016-06-29 FI FIEP16818224.4T patent/FI3322437T3/fi active
- 2016-06-29 CA CA3273336A patent/CA3273336A1/en active Pending
- 2016-06-29 PT PT168182244T patent/PT3322437T/pt unknown
- 2016-06-29 AR ARP160101975A patent/AR105485A1/es active IP Right Grant
- 2016-06-29 UY UY0001036759A patent/UY36759A/es unknown
- 2016-06-29 KR KR1020160081976A patent/KR102005456B1/ko active Active
- 2016-06-29 US US15/740,668 patent/US10696725B2/en active Active
- 2016-06-29 TW TW105120481A patent/TWI713541B/zh active
- 2016-06-29 CR CR20180034A patent/CR20180034A/es unknown
- 2016-06-29 AU AU2016287209A patent/AU2016287209B2/en active Active
- 2016-06-29 PY PY201601640586A patent/PY1640586A/es unknown
-
2017
- 2017-12-21 PH PH12017502393A patent/PH12017502393A1/en unknown
- 2017-12-27 IL IL256619A patent/IL256619B/en unknown
- 2017-12-27 CL CL2017003402A patent/CL2017003402A1/es unknown
- 2017-12-28 DO DO2017000318A patent/DOP2017000318A/es unknown
-
2018
- 2018-01-15 CO CONC2018/0000303A patent/CO2018000303A2/es unknown
- 2018-01-18 EC ECIEPI20183879A patent/ECSP18003879A/es unknown
-
2019
- 2019-07-24 KR KR1020190089584A patent/KR102395855B1/ko active Active
-
2020
- 2020-03-06 US US16/812,011 patent/US11261227B2/en active Active
-
2021
- 2021-03-05 JP JP2021034966A patent/JP7626393B2/ja active Active
-
2022
- 2022-01-14 US US17/576,519 patent/US11667688B2/en active Active
- 2022-03-13 IL IL291291A patent/IL291291B2/en unknown
-
2023
- 2023-01-20 CL CL2023000198A patent/CL2023000198A1/es unknown
- 2023-02-13 JP JP2023019975A patent/JP2023062043A/ja active Pending
- 2023-02-24 AU AU2023201118A patent/AU2023201118B2/en active Active
- 2023-06-27 CL CL2023001909A patent/CL2023001909A1/es unknown
- 2023-06-27 CL CL2023001910A patent/CL2023001910A1/es unknown
- 2023-06-27 CL CL2023001911A patent/CL2023001911A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7626393B2 (ja) | グルカゴン誘導体及びその持続型結合体を含む組成物 | |
| JP2019524675A5 (OSRAM) | ||
| AU2018200138B2 (en) | A Composition For Treating Diabetes or Diabesity Comprising Oxyntomudulin Analog | |
| AU2018203729B2 (en) | Composition For Treating Hyperlipidemia Comprising Oxyntomodulin Derivative | |
| AU2017289014B2 (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
| RU2016147505A (ru) | Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение | |
| IL268702A (en) | Use of a dual-acting GLP-1 / glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease | |
| RU2021109760A (ru) | Терапевтическое использование глюкагона и его комбинации | |
| HK40119597A (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
| HK40100949A (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
| NZ739250B2 (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
| HK1211856B (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
| NZ748034B2 (en) | A Composition For Treating Diabetes Or Diabesity Comprising Oxyntomodulin Analog |